What Sildenafil 1A Pharma Treats: Main Uses and Benefits

Sildenafil 1A Pharma may be part of symptomatic management within specific therapeutic domains where relief for conditions involving episodic or fluctuating manifestations is needed. It is commonly used to help with certain conditions marked by increased physiological stress, conditions where symptoms may intensify temporarily, and conditions presenting with systemic or localized discomfort.

---

Addressing Symptomatic Discomfort and Functional Strain

This medication is generally used in situations involving certain distressing symptoms and applied across domains where additional symptomatic support is relevant. The medicine helps address symptom clusters that may become intense or disruptive, providing supportive relief when symptoms interfere with routine activities. It assists with maintaining functional stability during phases of increased discomfort.

“The medicine is commonly used to help with short-term symptomatic assistance when discomfort or functional strain becomes noticeable.”

---

Support for Acute or Recurrent Episodes

Sildenafil 1A Pharma is considered relevant in clinical settings that involve acute or unstable symptom patterns, and often used during phases when symptoms become more noticeable. It contributes to improved comfort during periods of heightened symptoms, supporting patients to cope more steadily with symptom fluctuations.

---

Quick Fact: Support for Symptomatic Discomfort

Regulatory References

1. NIH MedlinePlus overview on Sildenafil

Official Eligibility Rules for Sildenafil 1A Pharma

Sildenafil 1A Pharma is officially approved for use in adult males (aged 18 and over). Regulatory bodies define strict population eligibility based on absolute contraindications and specific health conditions. The medicine is not indicated for women and not recommended for the pediatric population (under 18).

---

Populations Who Must Not Use Sildenafil 1A Pharma (Contraindications)

Contraindication	Condition or Concomitant Use
Nitrates/NO Donors	Use of any form of nitrates or nitric oxide donors (risk of severe hypotension).
Cardiovascular Risk	Patients for whom sexual activity is inadvisable due to severe cardiovascular disorders.
Ophthalmic History	History of vision loss in one eye due to NAION (Non-arteritic Anterior Ischaemic Optic Neuropathy) or certain hereditary degenerative retinal disorders.
Organ/Systemic Status	Severe hepatic impairment (Child-Pugh Class C), hypotension (blood pressure < 90/50 mmHg), or recent stroke or myocardial infarction (heart attack).

---

Restricted and Conditional Use

Use requires caution in patients with anatomical deformation of the penis (e.g., Peyronie's disease), pre-existing conditions predisposing to priapism (e.g., sickle cell anaemia), or those with bleeding disorders. Patients with severe renal impairment or mild to moderate hepatic impairment fall under restricted use and may require special consideration.

Interactions with other medicines and products

Sildenafil's primary interactions involve effects on blood pressure and drug metabolism.

---

Contraindicated Combinations

Sildenafil is strictly contraindicated for use with certain medicines due to the risk of severe, potentially fatal hypotension (dangerously low blood pressure):

• Nitrates and Nitric Oxide Donors: This includes all forms of organic nitrates (e.g., glyceryl trinitrate, isosorbide dinitrate) and recreational nitrites (poppers). Sildenafil significantly potentiates their blood pressure-lowering effects.
• Guanylate Cyclase (GC) Stimulators: Medicines like riociguat are also contraindicated, as the combination leads to additive systemic blood pressure reduction.

---

Combinations Requiring Caution

Consult a healthcare professional before combining Sildenafil with the following:

• Potent CYP3A4 Inhibitors: Drugs that block the enzyme responsible for sildenafil's metabolism (e.g., ritonavir, ketoconazole, itraconazole, erythromycin) can significantly increase the level of sildenafil in the blood, raising the risk of side effects. A lower starting dose of sildenafil (25 mg) is often recommended, and for ritonavir, the dosage must not exceed 25 mg within 48 hours.
• Alpha-blockers: Used to treat high blood pressure or enlarged prostate, alpha-blockers combined with sildenafil may cause symptomatic hypotension (dizziness, fainting). Patients should be stable on their alpha-blocker therapy before starting sildenafil at a lower initial dose.
• Other Treatments: Co-administration with other treatments for erectile dysfunction or other sildenafil-containing products (e.g., for pulmonary arterial hypertension) is not recommended due to a lack of safety data.

Selective Inhibition of the PDE5 Enzyme

Sildenafil's core action is the selective inhibition of the Phosphodiesterase type 5 (PDE5) enzyme, which is responsible for terminating specific chemical signals within vascular smooth muscle cells. This targeted enzyme blocking allows the essential second messenger, cyclic guanosine monophosphate (cGMP), to remain active for a longer duration than normal.

Amplification of Endogenous Vasodilation

By preventing the hydrolysis of cGMP, the drug essentially amplifies the body's natural Nitric Oxide (NO) signaling pathway, which physiologically mediates smooth muscle relaxation. This cascading molecular event leads to the sustained relaxation of the vascular smooth muscle cells, resulting in localized vasodilation and a subsequent reduction in vascular tone.

Mechanism-Dependent Physiological Effect

The mechanism is dependent on the presence of the initiating signal (NO release), meaning sildenafil is not a direct vasodilator but rather a potentiator of the body's own mechanism. This constraint limits the resulting physiological change to targeted areas where the pathway is already active, influencing the resulting systemic change.

How to Use Sildenafil 1A Pharma

Sildenafil 1A Pharma tablets are utilized according to a strict, as-needed dosing protocol, which focuses on administration context rather than daily scheduling. The approved route of administration is oral ingestion using the film-coated tablet. The maximum frequency is once per day, establishing a 24-hour interval between doses.

---

Administration and Timing

The dose is taken approximately one hour prior to the required activity, with a permissible window ranging from 30 minutes to 4 hours before. It is an essential procedural condition that sexual stimulation is present following administration for the medication to be effective. Taking the tablet with a high-fat meal may delay the onset of action, a factor that must be considered during planning.

---

Standard Dosing and Population Adjustments

The usual starting dose for adult use is 50 mg. The maintenance dose can range from a minimum of 25 mg up to a maximum single dose of 100 mg, determined by individual patient tolerability and efficacy.

Population-specific adjustments are required in the presence of certain impairments. A 25 mg starting dose should be considered for patients with severe renal impairment (creatinine clearance < 30 mL/min) or hepatic impairment. For older adults (65 years and older), no adjustment is typically needed, but a 25 mg starting dose may be considered. The tablets should be swallowed whole with water.

Research evidence / Overview of studies for Sildenafil 1A Pharma

Evidence for Use in Erectile Dysfunction (ED)

The medicine was studied for use in conditions marked by functional limitations of erectile function, and the evidence is largely built upon multiple short-term randomized controlled trials (RCTs). These studies were evaluated in research exploring how symptoms change over time when compared to an inactive substance (placebo). Outcomes were examined in adult men, including those with comorbidities such as diabetes. Research explored changes by relying on patient-reported scores and measures related to the initiation and maintenance of erection.

Long-term effects are not fully established. The initial short-term trials provide limited insight into observed responses in patients with severe, unstable heart or vascular issues, as these groups were generally excluded. Research provides limited insight into outcomes related to long-term physical discomfort.

---

Evidence for Use in Pulmonary Arterial Hypertension (PAH)

The medicine was studied for use in conditions characterized by fluctuating or episodic manifestations of high blood pressure in the lungs, known as Pulmonary Arterial Hypertension (PAH). The primary research consisted of short-term randomized controlled trials where the medicine was evaluated in settings that included a placebo group, typically over a period of 12 to 16 weeks. Studies explored outcomes reflecting daily functioning, chiefly by measuring the distance a patient could walk in six minutes (the 6MWD test), and monitored the time elapsed before the occurrence of a clinical worsening event.

Evidence exists for a group of pediatric patients (children aged 1 to 17 years) with PAH. However, subsequent findings regarding the long-term, high-dose use in the pediatric group were mixed, and regulatory bodies have noted that certainty remains low for this specific application.

---

What is Still Uncertain About the Research Base

While research provides insight into short-term changes and was studied for its impact on functional outcomes, long-term effects are not fully established for certain outcomes, particularly regarding outcomes related to long-term status in adult PAH populations. Results apply only to the populations studied, meaning findings may not fully translate to patients who were excluded from the core trials. Subgroup findings are uncertain for high-dose chronic use in children with PAH.

Key Studies & References

1. Sildenafil: MedlinePlus Drug Information

Common questions about Sildenafil 1A Pharma (FAQ)

Q: What are the official medical conditions that Sildenafil is approved to treat?

According to official regulatory documents, Sildenafil is formally indicated for the treatment of erectile dysfunction in adult men. It is also approved for the treatment of pulmonary arterial hypertension (PAH), which is a specific type of high blood pressure affecting the arteries in the lungs.

Q: What factors can affect the overall effectiveness of Sildenafil?

Official prescribing information notes several factors that can influence the medicine's action. The effectiveness of Sildenafil is linked to the presence of sexual stimulation. Taking the tablet with a high-fat meal is documented to delay the time it takes for the drug to start working. Additionally, patient factors like age and the status of certain organ functions (such as the liver or kidneys) can affect how the drug is concentrated in the body.

Q: What is the known risk of priapism (a prolonged erection) when using Sildenafil?

Priapism is defined as an erection that lasts longer than four hours. Official documents list priapism as a rare but serious adverse reaction associated with Sildenafil use. Regulatory agencies note that the medicine is used with caution in patients who have pre-existing conditions that make them more susceptible to priapism, such as sickle cell anaemia.

Q: What is the documented interaction between Sildenafil and grapefruit or grapefruit juice?

Regulatory information indicates that grapefruit juice is a mild inhibitor of the CYP3A4 enzyme, which is responsible for breaking down Sildenafil in the liver. Consuming grapefruit juice may change the concentration of Sildenafil in the blood by interfering with its metabolism. This information is included in the official product labeling.

Q: Does Sildenafil interact with herbal supplements or common over-the-counter products?

Official drug warnings primarily focus on prescription medicines that interact with the CYP3A4 metabolic enzyme. Regulatory documentation describes the risk of interaction with products that affect this enzyme. This includes certain herbal supplements, which is why regulatory warnings exist regarding this type of metabolic pathway interaction.

Q: How does the body naturally process and eliminate Sildenafil after it has been used?

Sildenafil is first metabolized, or broken down, by enzymes in the liver. The majority of the drug and its primary active by-product are then eliminated from the body via the faeces, accounting for about 80% of elimination. A smaller amount, roughly 13%, is eliminated via the urine.

Q: What happens if someone accidentally takes more Sildenafil 1A Pharma than intended?

According to official labeling and clinical studies, single doses significantly higher than the maximum recommended dose have been studied. Adverse reactions observed were similar to those seen at lower doses, but regulatory reports indicate these reactions were increased in both incidence and severity.

Q: Is it necessary to avoid alcohol entirely when using Sildenafil 1A Pharma?

Regulatory sources note that using Sildenafil simultaneously with alcohol may increase the risk of a condition called orthostatic hypotension. This means there is a potential for feeling dizzy or faint when standing up suddenly. Official documentation notes the potential risk but does not contain an explicit requirement for complete avoidance of alcohol.

Official Storage and Disposal Requirements

The storage and disposal instructions for Sildenafil 1A Pharma are established by regulatory authorities to ensure product integrity and public safety.

Child Safety Storage

The primary mandatory storage requirement is to keep this medicine out of the sight and reach of children at all times.

Handling and Packaging

The tablets are packaged in Aclar/Aluminium blister packs, which provide necessary protection for the medication. Official regulatory documents state no special requirements for the general handling of the tablets.

Disposal Rules

For disposal, the regulatory Summary of Product Characteristics states no special requirements are necessary. This indicates that the product should be disposed of in accordance with standard local household waste procedures, unless otherwise instructed by a healthcare professional or local authority.